Foundation for Global Skin Health Strategies


of Directors

Advisory Board

Advisory Board

Foundation Board members meeting at Harvard Club in New York.

John G. Callahan (left) and William M. Noé attend presentation on advances in the treatment of Melanoma.


  • American Academy
    of Dermatology
  • American Contact Dermatitis Society
  • The American Society for Clinical Investigation
  • Biopelle
  • Ferndale Laboratories Inc.

Business Advisory Board

Marina D'Arezzo

Marina D'Arezzo has depth of experience in real estate investment sales and in hospitality brokerage. Her expertise includes positions as designer / design coordinator for apparel firms with international distribution. A published author in French on the subject of nutrition, Marina D'Arezzo also co-developed what has become a standard study tool to prepare for the Board exam for third year Residents in Dermatology, Boards-in-a-Box. She co-created and served as Editor-in-Chief of publications sponsored by dermatology companies for distribution to practicing Dermatologists and Podiatrists in the US. She currently owns a pharmaceutical brokerage company which has caused the introduction and commercialization of cosmeceutical products internationally. In addition to Briarcliff College, her studies include Neuchatel, Switzerland, La Sorbonne, Paris and London's Royal College of Art. She has written two children's apps for the iPhone, licensing the e-rights to Ziggy, the internatinally renown comic strip character. "Ziggy's Best Birthday" brings the message of safe play in the sun; the second app brings the skin protection message in the context of green living. Her memberships include the Metropolitan Club in New York and the Cercle de L'Union Interalliée in Paris.

John Callahan

John G. Callahan is an active entrepreneur who has invested in and helped manage six startup companies. These include OraGen Corporation, which was sold to Enzo Biochem and Hapten Pharmaceuticals, which is presently conducting clinical trials to develop a topical immunomodulator to treat HPV related skin diseases, HIV and certain cancers. John has over 20 years experience in pharmaceutical marketing as a principal and as chairman of Callahan Chemical Company.

He is a past President of the Philadelphia Drug Exchange, a major pharmaceutical trade association. John earned an MBA degree from the University of Pennsylvania's Wharton School and a B. A. from Villanova University.

Alfred Marchal

In his more than 30 years of experience in the health care industry, Alfred Marchal has held roles from research scientist to Managing Director. Today, he owns several pharmaceutical companies. Their wide range of advanced novel and patented technologies have been developed and produced in association with renowned European Universities including several throughout France and Belgium. Mr. Marchal lectures internationally at medical and biotechnology meetings and seminars on subjects as wide-ranging as chemistry, pharmaceutics, pharmacology and nanobiology. Mr. Marchal is the inventor of advanced treatments for post-traumatic and age-related hematoma, disorders of pigmentation and anti-aging therapies for the skin.

William M. Noé

William Noé has over 40 years of experience in real estate development, oil & gas investment and venture capital finance. Mr. Noé founded Asset Development Corporation in 1974 and has since served as its Chief Executive Officer with primary focus on the syndication of real estate properties and energy projects and the financial structuring of early stage technology companies. Mr. Noé is also a Managing Director of Vantage Investments Group, Inc. of New York City, a merchant banking firm that provides business development consulting, financial structuring advice and capital funding to new business ventures, primarily in the technology sector. Mr. Noé serves as an officer and director of the Financial Analysts and Money Managers Society, Inc. (FAMMS), a non-profit organization comprised of senior members of the financial community.

Mr. Noé is the Chief Financial Officer and founder-shareholder of MMPN Investment Corporation, a company based in the Republic of South Africa conducting business in the sale of precious commodities, such as gold and diamonds, refined and crude oil and other commodities, and is the CFO of its affiliate in the United States, SETOM International Import & Export Corporation. He is also the President of AmeriStar Network, Inc., a public company active in developing and promoting Internet-based solutions for the mortgage, credit union and independent community bank industries in the United States. From 2001 to 2004, Mr. Noé was also a Managing Director of Chapman, Spira & Carson, LLC, a New York City based investment consulting firm, where Mr. Noé's primary responsibilities were to direct the firm's research and business planning activities and coordinate capital raising efforts.

Mr. Noé holds a M.B.A. (Finance) from the Harvard Business School and a B.A. (Economics) from the University of Southern California. He received accreditation from the State of New York to teach courses in Real Estate and has taught at the New School for Social Research in New York City and for the National Association of Home Builders nationally.

Daryl Spinner, Ph.D

Dr. Daryl Spinner has experience leading international teams of scientists in biomedical R&D and has successfully secured funding from both private and government sources. He served as Research Scientist and Group Leader at the New York State Institute for Basic Research (NYS IBR) in Staten Island, NY from 2001 to 2008. While in that role, Dr. Spinner won a number of awards for his research. He developed patents and products for Alzheimer's and mad cow disease diagnostics and therapeutics and has produced more than 35 publications and conference abstracts of his research. He is a member of the NY Academy of Sciences, the Society for Neuroscience and the International Society to Advance Alzheimer's Research and Treatment. Dr. Spinner is currently pursuing his MBA in Health Sector Management and Finance at Duke University, The Fuqua School of Business in NC. At Fuqua he serves as the Director of Communication and Technology for the Asset Management Club, as well as the Healthcare Sector Analyst for the club's Reynold's Trust stock portfolio. Dr. Spinner also serves as a Scientific Consultant at the NYS IBR and is Principal Investigator on a Department of Defense grant to study the molecular and environmental causes of autism. He does consulting to small biotech firms in NC on scientific and business issues part time. Dr. Spinner holds a PhD in Molecular and Cellular Pharmacology from the State University of NY at Stony Brook, NY.